New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
04:55 EDTBAX, BAX, BAX, BAX, NVDQ, NVDQ, NVDQ, NVDQ, RTIX, RTIX, RTIX, RTIX, SYK, SYK, SYK, SYK, TFX, TFX, TFX, TFX, GIVN, GIVN, GIVN, GIVN, EW, EW, EW, EW, ETRM, ETRM, ETRM, ETRM, ECIA, ECIA, ECIA, ECIA, COV, COV, COV, COV, CNMD, CNMD, CNMD, CNMD, CFN, CFN, CFN, CFN, CADX, CADX, CADX, CADX, BSX, BSX, BSX, BSX, NPSP, NPSP, NPSP, NPSPSociety of American Gastrointestinal & Endoscopic Surgeons holds annual meeting
2014 Annual Meeting of SAGES is being held in Salt Lake City, Utah on April 2-5.
News For BAX;BSX;CADX;CFN;CNMD;COV;ECIA;ETRM;EW;GIVN;TFX;SYK;RTIX;NVDQ;NPSP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 24, 2014
08:46 EDTSYKStryker weighing renewed Smith & Nephew bid, Bloomberg reports
Subscribe for More Information
08:12 EDTNPSPNPS Pharmaceuticals says Teduglutide granted orphan drug designation in Japan
Subscribe for More Information
07:46 EDTSYKPfizer seen set to move on from AstraZeneca as restrictions lift, Telegraph says
Subscribe for More Information
November 21, 2014
13:31 EDTCOVCovidien announces mailing of definitive joint proxy statement, prospectus
Covidien (COV) announced, for purposes of the Irish Takeover Rules, that the definitive joint proxy statement of Covidien and Medtronic (MDT), which also serves as a prospectus of Medtronic Holdings Limited and comprises Covidienís scheme circular required under Irish law is being sent today to Covidien and Medtronic shareholders. As previously announced, on June 15, Covidien and Medtronic entered into a definitive agreement pursuant to which Medtronic Holdings Limited, a new holding company incorporated in Ireland that will be renamed Medtronic plc, will acquire Covidien and Medtronic. The joint proxy statement/prospectus will contain important information about the transaction for shareholders of both companies, as well as notices of the shareholder meetings and instructions on voting online, by mail, by telephone or in person.
09:27 EDTSYKRumors of Smith & Nephew bid from Stryker intensify, Daily Mail says
Shares of Smith & Nephew (SNN) rallied in U.K. trading amid "intensified" rumors that Stryker (SYK) will make a GBP 13B plus bid for its rival when its Takeover Panel restrictions are removed at month end, according to The Daily Mail's "This is Money." Reference Link
November 20, 2014
09:07 EDTCFNBecton Dickinson, CareFusion announce expiration of HSR act waiting period
Becton, Dickinson (BDX) and CareFusion (CFN) announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with BD's proposed acquisition of CareFusion expired on November 19. The expiration of the HSR Act waiting period satisfies a condition to the proposed acquisition. The proposed acquisition remains subject to certain other conditions and approvals.
07:31 EDTBSXBoston Scientific should be bought on weakness, says RBC Capital
Subscribe for More Information
07:13 EDTNVDQCanaccord to hold a forum
Subscribe for More Information
05:14 EDTCOVCovidien achieves CE Mark for Nellcor Bedside SpO2 Patient Monitoring System
Subscribe for More Information
November 19, 2014
12:11 EDTBSXBoston Scientific says Synergy stent met primary endpoint in trial
In the first successful U.S. pivotal trial of a bioabsorbable polymer stent, the Boston Scientific SYNERGY Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System met its primary endpoint in this non-inferiority study, which evaluated the one-year rate of target lesion failure. Additionally, favorable rates for key secondary endpoints were observed with the SYNERGY Stent. Dean Kereiakes, M.D., F.A.C.C., F.S.C.A.I., the principal investigator for the EVOLVE II Trial, presented the study results today in a Late Breaking Clinical Trial session at the American Heart Association Scientific Session 2014 in Chicago. Key findings for the SYNERGY Stent from the EVOLVE II Trial include the following: At 12 months, the TLF rate was 6.4% per protocol and 6.7% for intent-to-treat. Stent Thrombosis was rare, with Definite or Probable ST occurring in only 0.4% of patients through one year. No Definite ST occurred after 24 hours.
08:15 EDTCOVMedtronic reported solid Q2 results, says Bernstein
Bernstein notes that Medtronic's (MDT) sales growth accelerated to 5%, and the firm thinks the company's market share of the ICD market is poised to increase next quarter. Bernstein views Medtronic as "a strong buy" into the close of its acquisition of Covidien (COV). The firm reiterates an Outperform rating on Medtronic.
06:54 EDTCOVMedtronic reiterated as a top pick at JPMorgan
Subscribe for More Information
06:30 EDTBSXJohnson & Johnson, Boston Scientific trial set to start tomorrow, Reuters says
Subscribe for More Information
November 18, 2014
12:08 EDTCOVOn The Fly: Midday Wrap
Subscribe for More Information
11:35 EDTBSXBoston Scientific November volatility elevated into investor day
Subscribe for More Information
09:08 EDTCOVMedtronic says regulatory processes for Covidien deal 'all on track'
Subscribe for More Information
07:37 EDTBAX, BSXStifel to hold a conference
Subscribe for More Information
07:20 EDTCOVMedtronic confirms commitment to Covidien transaction
Subscribe for More Information
06:08 EDTBSXBoston Scientific to host investor meeting
Investor meeting to be held on November 19 at 2 pm. Webcast Link
November 17, 2014
09:08 EDTBSXBoston Scientific announces first U.S. procedures with Symphion completed
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use